FDA Approved First Oral PCSK9-Inhibitor for Cholesterol
Adults with high LDL cholesterol now have an oral medication option to help reach their target levels.
Updated on Oct. 5, 2026 in Heart Disease
Live Poll
Would you prefer a daily pill over regular injections to manage your cholesterol levels?
The FDA has approved Lipfendra, a new oral medication known as enlicitide, to help adults lower their LDL cholesterol. This treatment provides a new daily option for patients, including those with familial hypercholesterolemia, who struggle to manage their cholesterol levels.
Why it matters
Enlicitide offers a significant shift in treatment access by providing a daily pill for patients who prefer to avoid injectable cholesterol medications. It is designed to help those who have not reached their LDL goals despite taking standard statin therapy.
In a 52-week clinical trial involving adults where 97% were already taking statins, participants taking 20mg of enlicitide daily saw their average LDL cholesterol levels drop from 95 mg/dL to 39 mg/dL. These preliminary findings demonstrate significant LDL lowering, though outcomes regarding cardiovascular events remain under investigation.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of drugs.
Lipfendra
The brand name for enlicitide, a newly approved oral PCSK9-inhibitor for managing LDL cholesterol.
UT Southwestern Medical Center
A leading academic medical center involved in the clinical research and development of cholesterol-lowering therapies.
The details
Enlicitide, marketed as Lipfendra, acts as an oral PCSK9-inhibitor. The medication functions by binding to the PCSK9 protein, which prevents it from attaching to LDL receptors in the body. By blocking this interaction, the drug increases the number of receptors available to remove LDL cholesterol from the bloodstream.
Timeline
2015: The FDA approved the first injectable PCSK9-inhibitor drugs.
March 2026: Medical associations published updated cholesterol management guidelines.
24 weeks: Duration used to measure the primary LDL cholesterol reduction in the trial.
52 weeks: Total duration of the clinical trial for enlicitide.
Health Landscape
The introduction of Lipfendra marks a significant shift away from the delivery method established by the 2015 approval of injectable PCSK9-inhibitor drugs. It expands the current toolkit for cholesterol management by offering an oral alternative to existing injectable standards of care.
If you are currently struggling to reach your target LDL level of 55 mg/dL or lower, discuss with your doctor whether an oral PCSK9-inhibitor might be appropriate for your treatment plan. Keep in mind that while this drug effectively lowers LDL, its long-term impact on preventing heart attacks remains unknown.
The takeaway
Lipfendra represents a new daily option for those managing high cholesterol who have not reached their goals with statins alone. Talk to your physician about your current LDL numbers and whether you meet the criteria for this new class of medication.
Further reading
For more information on managing your levels, visit the Heart Disease section.
Live Poll
Would you prefer a daily pill over regular injections to manage your cholesterol levels?
